Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Familial Adenomatous PolyposisMap SyndromeLynch SyndromeHnpccColorectal Cancer
Interventions
OTHER

Epi proColon Testing

"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Epigenomics, Inc

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT02198092 - Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes | Biotech Hunter | Biotech Hunter